GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Editas Medicine Inc (FRA:8EM) » Definitions » Cyclically Adjusted PB Ratio

Editas Medicine (FRA:8EM) Cyclically Adjusted PB Ratio : 0.28 (As of Jun. 01, 2025)


View and export this data going back to 2016. Start your Free Trial

What is Editas Medicine Cyclically Adjusted PB Ratio?

As of today (2025-06-01), Editas Medicine's current share price is €1.563. Editas Medicine's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was €5.53. Editas Medicine's Cyclically Adjusted PB Ratio for today is 0.28.

The historical rank and industry rank for Editas Medicine's Cyclically Adjusted PB Ratio or its related term are showing as below:

FRA:8EM' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.18   Med: 0.33   Max: 0.96
Current: 0.3

During the past years, Editas Medicine's highest Cyclically Adjusted PB Ratio was 0.96. The lowest was 0.18. And the median was 0.33.

FRA:8EM's Cyclically Adjusted PB Ratio is ranked better than
77.83% of 672 companies
in the Biotechnology industry
Industry Median: 1.49 vs FRA:8EM: 0.30

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Editas Medicine's adjusted book value per share data for the three months ended in Mar. 2025 was €0.690. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €5.53 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Editas Medicine Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Editas Medicine's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Editas Medicine Cyclically Adjusted PB Ratio Chart

Editas Medicine Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 0.22

Editas Medicine Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.79 0.59 0.22 0.20

Competitive Comparison of Editas Medicine's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Editas Medicine's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Editas Medicine's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Editas Medicine's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Editas Medicine's Cyclically Adjusted PB Ratio falls into.


;
;

Editas Medicine Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Editas Medicine's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=1.563/5.53
=0.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Editas Medicine's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Editas Medicine's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book=Book Value per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.69/134.9266*134.9266
=0.690

Current CPI (Mar. 2025) = 134.9266.

Editas Medicine Quarterly Data

Book Value per Share CPI Adj_Book
201506 0.000 100.684 0.000
201509 3.185 100.392 4.281
201512 -2.137 99.792 -2.889
201603 5.141 100.470 6.904
201606 4.713 101.688 6.254
201609 4.258 101.861 5.640
201612 3.563 101.863 4.720
201703 4.742 102.862 6.220
201706 4.024 103.349 5.254
201709 3.565 104.136 4.619
201712 3.950 104.011 5.124
201803 4.297 105.290 5.507
201806 4.182 106.317 5.307
201809 4.049 106.507 5.129
201812 4.257 105.998 5.419
201903 3.928 107.251 4.942
201906 3.470 108.070 4.332
201909 3.733 108.329 4.650
201912 4.345 108.420 5.407
202003 3.874 108.902 4.800
202006 6.102 108.767 7.570
202009 6.023 109.815 7.400
202012 5.171 109.897 6.349
202103 7.943 111.754 9.590
202106 7.469 114.631 8.791
202109 7.300 115.734 8.511
202112 7.160 117.630 8.213
202203 6.787 121.301 7.549
202206 6.407 125.017 6.915
202209 6.092 125.227 6.564
202212 4.945 125.222 5.328
202303 4.298 127.348 4.554
202306 4.523 128.729 4.741
202309 4.136 129.860 4.297
202312 3.915 129.419 4.082
202403 3.294 131.776 3.373
202406 2.615 132.554 2.662
202409 1.917 133.029 1.944
202412 1.550 133.157 1.571
202503 0.690 134.927 0.690

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Editas Medicine  (FRA:8EM) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Editas Medicine Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Editas Medicine's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Editas Medicine Business Description

Traded in Other Exchanges
Address
11 Hurley Street, Cambridge, MA, USA, 02141
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.

Editas Medicine Headlines

No Headlines